Theranautilus, a deep-tech innovator specializing in nanorobotics for healthcare, has raised ₹10.13Cr in seed funding. The round was led by pi Ventures, with participation from Golden Sparrow Ventures and angel investors, including Abhishek Goyal, CEO of Tracxn, and Lalit Keshre, CEO of Groww. The funds will be used to commercialize nanorobotics-based medical devices, initially focusing on dental care, advancing the company's go-to-market strategy, and exploring broader healthcare applications.

Incubated at the Indian Institute of Science (IISc) and founded in 2020 by Ambarish Ghosh, Dr. Debayan Dasgupta, and Dr. Peddi Shanmukh Srinivas, Theranautilus aims to tackle critical dental health challenges such as hypersensitivity, which affects over 2 billion people globally and represents a $6 billion market.

Unlike traditional treatments that rely on specialized toothpaste, Theranautilus’s technology uses precision-manufactured nanorobots to deliver biocompatible materials directly to damaged dental tissues. These materials are externally triggered to form bio-mimetic structures, offering long-lasting relief in just a 10-minute procedure. The approach has shown promising results in animal trials, with human trials planned for 2025.

Ambarish Ghosh, Co-founder of Theranautilus, highlighted, “Our nanorobotic platform represents a transformative step in healthcare, providing precision treatments that go beyond conventional solutions.”

With international patents and ambitious plans, Theranautilus is also exploring applications in cancer therapy and other diseases, aiming to redefine precision healthcare with theranostics-based interventions.